Company news

Rocket Pharmaceuticals, Inc. news in 2026

Rocket Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference

October 15, 2026

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

October 7, 2026

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

October 6, 2026

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease

September 15, 2026

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

August 10, 2026

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

August 3, 2026

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

June 12, 2026

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

May 7, 2026

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

April 28, 2026

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I

March 30, 2026

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

March 26, 2026

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

February 25, 2026

Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 4, 2026

Decks in 2026